Jeanmarie’s Illustrative Career In Leadership And Scientific Innovations

On April 2015, the media featured news about the first breakthrough of Amphivena Therapeutics Incorporation. The developments were in collaboration with Janseen Biotech on LinkedIn. The two parties tested the cancer antigen on a selected candidate to create the clinically perfect treatment for hematologic malignancies. The clinical candidate received certification from RECRUIT-TandAb and Affirmed GmbH. The results of the experiments proved successful, and Amphivena received an undisclosed amount to cover the costs of research, development, and labor. The chief executive officer and president of Amphivena Therapeutics, Jeanmarie Guenot, stated that the firm is enthusiastic to progress the cancer treatment medicines and therapies.

Jeanmarie Guenot utilizes her experience of more than 20 years in the biotechnological and pharmaceutical industries to lead Amphivena to achieve significant innovations for cancer. She previously worked for Atlas Venture as a venture capitalist, firm developer, and investment manager. After leaving Atlas, JeanMarie joined PDL BioPharma as the vice president of business and corporate development. Her role included overseeing the creation of licensing, acquisitions, alliance management, and mergers. She worked at Hoffman-La Roche between 2008 and 2009 as a chief scientist and business advisor before branching out as a solo scientist and entrepreneur. Jeanmarie Guenot facilitated the contract between Hoffman-La Roche and PDL to develop and commercialize drugs. As a result of her diligent and smart work, JeanMarie received the 2005 BioBusiness Network Innovative and Bio-Partnering award. In 2006, she won the Deal of Distinction from Licensing Executive Society.

In 2009, JeanMarie Guenot started SKS Ocular, LLC and managed it as a partner for three years. SKS Ocular specialized in developing technologies that create ocular drugs to treat glaucoma, macular degeneration, dry AMD and ocular inflammation. She has worked in firms in both the public and private platforms, specifically pharmaceutical R & D, corporate and commercial development enterprises, business development project and alliance development and venture capitalism. By working for SKS Ocular as the chief operating officer, JeanMarie honed her skills in developing ophthalmologic firms which she uses to expand Amphivena’s drug development works. JeanMarie studied at the University of California in San Francisco where he graduated with a degree in chemistry. After receiving her Ph.D. in the same field, she joined the Wharton School of the University of Pennsylvania to pursue and MBA.

Read more: Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies